Lilly also said that revenues would be between $21.8 billion and $22.8 billion, largely because of an expected loss of $3 billion in Zyprexa sales.
"This is a $500 million greater decline than we had forecast," Chris Schott, an analyst at J.P. Morgan, wrote in a research note. He called the updated guidance "disappointing" and a "top-line miss."
Friday, January 06, 2012
Lilly's financial forecast in wake of Zyprexa patent loss is a downer for market | The Indianapolis Star | indystar.com